MedPath

GILEAD SCIENCES SL

🇺🇸United States
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain
Clinical Trials
Related News

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2013-04-15
Last Posted Date
2021-02-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
74
Registration Number
NCT01831427
Locations
🇺🇸

Ehrhardt Clinical Research, LLC, Belton, Missouri, United States

🇺🇸

Delta Research Partners LLC, Monroe, Louisiana, United States

🇷🇴

Institute of Pulmonology "Marius Nasta", Bucharest, Romania

and more 13 locations

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Phase 2
Completed
Conditions
Chronic Hepatitis C
Interventions
Drug: SOF
Drug: LDV/SOF
Drug: VEL
Drug: Peg-IFN
First Posted Date
2013-04-09
Last Posted Date
2018-11-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
359
Registration Number
NCT01826981
Locations
🇳🇿

Auckland Clinical Studies Ltd., Auckland, New Zealand

🇳🇿

Christchurch Clinical Studies Trust, Christchurch, New Zealand

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Phase 1
Completed
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2013-03-26
Last Posted Date
2013-08-29
Lead Sponsor
Gilead Sciences
Target Recruit Count
33
Registration Number
NCT01817985
Locations
🇵🇷

Investigational Site, San Juan, Puerto Rico

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Phase 3
Completed
Conditions
HIV
HIV Infections
Interventions
First Posted Date
2013-03-26
Last Posted Date
2020-03-02
Lead Sponsor
Gilead Sciences
Target Recruit Count
252
Registration Number
NCT01818596
Locations
🇺🇸

Peter J Ruane, MD, Inc, Los Angeles, California, United States

🇺🇸

Mercer University, Macon, Georgia, United States

🇺🇸

Anthony Mills MD, Inc, Los Angeles, California, United States

and more 67 locations

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Phase 3
Completed
Conditions
HIV
HIV Infections
Interventions
Drug: EFV/FTC/TDF
Drug: ATV
Drug: FTC/TDF
First Posted Date
2013-03-21
Last Posted Date
2021-04-13
Lead Sponsor
Gilead Sciences
Target Recruit Count
1443
Registration Number
NCT01815736
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Southwest Infectious Disease Clinical Research, Inc., Dallas, Texas, United States

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 164 locations

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Phase 2
Completed
Conditions
Hepatitis C
Interventions
Drug: SOF
First Posted Date
2013-03-11
Last Posted Date
2014-09-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
47
Registration Number
NCT01808248
Locations
🇺🇸

Alamo Medical Research, San Antonio, Texas, United States

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Phase 1
Completed
Conditions
Pancreatic Cancer
Esophagogastric Cancer
Non-small Cell Lung Cancer
Breast Cancer
Colorectal Cancer
Interventions
First Posted Date
2013-03-04
Last Posted Date
2020-06-02
Lead Sponsor
Gilead Sciences
Target Recruit Count
236
Registration Number
NCT01803282
Locations
🇺🇸

Comprehensive Blood and Cancer Center, Bakersfield, California, United States

🇺🇸

University of Southern California (USC), Los Angeles, California, United States

🇺🇸

Parkview Research Center, Fort Wayne, Indiana, United States

and more 15 locations

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

Phase 1
Completed
Conditions
RSV Infection
Interventions
First Posted Date
2013-02-28
Last Posted Date
2013-06-10
Lead Sponsor
Gilead Sciences
Target Recruit Count
8
Registration Number
NCT01801293
Locations
🇺🇸

Investigational Site, Madison, Wisconsin, United States

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase 2
Terminated
Conditions
Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Non-FL Indolent Non-Hodgkin's Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2013-02-27
Last Posted Date
2020-11-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
326
Registration Number
NCT01799889
Locations
🇺🇸

Memorial Cancer Institute, Hollywood, Florida, United States

🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 45 locations

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Phase 3
Completed
Conditions
HIV
HIV Infections
Interventions
Drug: E/C/F/TDF Placebo
Drug: E/C/F/TAF Placebo
First Posted Date
2013-02-22
Last Posted Date
2020-03-02
Lead Sponsor
Gilead Sciences
Target Recruit Count
872
Registration Number
NCT01797445
Locations
🇺🇸

Kaiser Permanente - Los Angeles Medical Center, Los Angeles, California, United States

🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Mercer University, Macon, Georgia, United States

and more 113 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy